Uncategorized

SAN DIEGO, CA – January 20, 2025 – Tanvex BioPharma, Inc.  (“Tanvex”), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion of its acquisition of Bora Biologics Co., Ltd. (“Bora Biologics”), a subsidiary of Bora Pharmaceuticals. Following this acquisition, Tanvex’s CDMO services will...

42nd Annual J.P. Morgan Healthcare ConferenceBora Pharmaceuticals has been invited to participate in the prestigious J.P. Morgan Healthcare Conference and will be hosting a company presentation on January 16, 2025, at 2:15pm PST. We invite you to join us at the session via the link below to hear the insights shared by Bora Chairman and CEO, Bobby Sheng. Bora Company Presentation